O-060. Hemodynamic effects of continuous intravenous infusion of growth hormone in patients with severe heart failure

A. Giustina, M. Volterrani, R. Lorusso, F. Manelli, P. Desenzani, G. Romanelli, A. Giordano

Research output: Contribution to journalArticlepeer-review

Abstract

Experimental data show that growth hormone (GH) improves cardiac contractility and reduces peripheral vascular resistances in a rat model of heart failure (HF). Moreover, it has been recently shown that long-term (3 months) GH treatment improves several parameters of cardiac function in patients with dilatative cardiomyopathy. Aim of the study was to evaluate the acute hemodynamic effects of acute continuous i.v. GH infusion in 12 male patients with DOS: ischemic HF, mean age 63±7 yrs (range 73-49) and mean ejection fraction (ECHO) 20.6%±6.5% (range 36-11%). All patients were in stable chronic therapy with diuretics, digoxin and ACE-inhibitors. We evaluated, in all subjects, the overnight (every 20 min from 10 p.m. to 6 a.m.) spontaneous GH secretion (IRMA Nichols, USA) and the hemodinamic parameters via Swan-Ganz right cardiac and left radial arterial catheterization for 24 hours at baseline and during the following 24 hours of continuous iv infusion of recombinant human GH (Humatrope; Eli Lilly, Italy; 0.1 Ul/kg/24 h). Furthermore, hemodynamic values and GH serum concentrations were monitored every 4 hours during the GH iv infusion. After 24 hours of GH infusion, we found a significant increase as compared to baseline parameters in cardiac output (CO 5.7±2 vs 3.9±1.1 l/min, p

Original languageEnglish
Pages (from-to)32
Number of pages1
JournalEndocrinology and Metabolism, Supplement
Volume4
Issue numberA
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'O-060. Hemodynamic effects of continuous intravenous infusion of growth hormone in patients with severe heart failure'. Together they form a unique fingerprint.

Cite this